CTSOCytoSorbents Corporation

Cash burn improved as company pursues FDA approval for DrugSorb-ATR device.

Moby summary of Cytosorbents Corporation's Q2 2026 earnings call

CytoSorbents Corp (CTSO) slashes cash burn to $200K, boosts gross margins to 73%, and advances DrugSorb ATR and Hemodefen BGA regulatory pathways despite STAR-T trial setback.

Moby summary of Cytosorbents Corporation's Q1 2026 earnings call

Despite geopolitical disruptions and regulatory hurdles, CytoSorbents Corp (CTSO) showcases resilience with revenue growth and operational improvements.

CytoSorbents (NASDAQ:CTSO) reported first-quarter financial results on Wednesday. The transcript from the company's first-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. View the webcast at https://app.webinar.net/KbgRLmJk8ow Summary Cytosorbents Corp reported a 2% year-over-year revenue growth to $8.9 million for Q1 2026, despite geopolitical disruptions affecting dis

Need a quote from a Motley Fool analyst? Cytosorbents is built around a differentiated blood purification platform designed to remove toxins and harmful substances from the bloodstream in critically ill patients.

Moby summary of Cytosorbents Corporation's Q4 2025 earnings call

Despite a modest revenue increase and strong international sales, CytoSorbents Corp (CTSO) faces hurdles in Germany and FDA resubmission efforts.

The Princeton, New Jersey-based company said it had a loss of 9 cents per share. The blood purification therapy company posted revenue of $9.2 million in the period. For the year, the company reported a loss of $8.2 million, or 13 cents per share.